We identifi ed children <16 years (y) diagnosed with IBD 1999-2010 from health administrative data in fi ve provinces (Alberta, Manitoba, Nova Scotia, Ontario, Quebec), comprising 79.2% of the Canadian population. Standardized incidence and prevalence were calculated per 100,000 children. Annual percentage change (APC) in incidence and prevalence were determined using Poisson regression analysis. Provincial estimates were meta-analyzed using random-effects models to produce national estimates.
INTRODUCTION
Th e incidence and prevalence of childhood-onset infl ammatory bowel disease (IBD) has risen rapidly over the past two decades ( 1 ) . While previously considered rare in children, IBD has emerged as a global disease in developed and developing nations ( 2, 3 ) . Th e increasingly early onset of Crohn's disease (CD) and ulcerative colitis (UC) raises important questions regarding the role of early-life factors in the pathogenesis of IBD ( 4 ) . It also represents a signifi cant burden to health care systems ( 5 ) , because the treatment of childhood-onset IBD is more expensive in the long-term ( 6 ) .
Canadian health administrative data represent an unprecedented opportunity to assess the trends in epidemiology and health services utilization of children with IBD. Each Canadian province has independent single-payer health systems, so all legal residents of each province are included within health administrative data. Independently, the trends of pediatric IBD have been described in individual Canadian provinces (7) (8) (9) (10) (11) (12) . However, application of the same case identifi cation algorithm in diff erent jurisdictions without additional validation can result in misclassifi cation bias ( 13 ) . Even though the health administrative data from each province are similar in database population and data structure, research using these data has revealed diff erences in trends. For example, studies from Ontario have consistently reported increasing incidence in children and teenagers (7) (8) (9) , with less pronounced increased incidence in adults ( 9 ) . However, research from Quebec ( 12 ) and Nova Scotia ( 11 ) has demonstrated stable incidence in children and decreased incidence in adults. Th ese disparities may be due to diff erences in methodology ( 13 ) , or due to true variation. In addition, single-province studies may not be powered to demonstrate trends in age groups where IBD is rare, such as those with disease onset prior to the age of 10 years.
Th e Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC) was formed to provide national-level information using distributed network analysis of multiple Canadian provincial health administrative data, reducing heterogeneity of methods and improving power for smaller populations or uncommon outcomes. Th e aim of this study was to determine trends in incidence and prevalence of childhood-onset IBD in Canada to determine the burden of IBD in Canadian children.
METHODS

Study design and setting
Th is study was approved by the research ethics boards of the Children's Hospital of Eastern Ontario, the Ottawa Hospital, University of Manitoba, Dalhousie University, Conjoint Health Research Ethics Board of the University of Calgary, and the Montreal Jewish General Hospital. In addition, this study was reviewed for privacy concerns by Manitoba Health's Health Information Privacy Committee, the Privacy Offi cer of the Institute for Clinical Evaluative Sciences (ICES), and the Comission d'acces a l'information du Quebec (CAI). We conducted a retrospective cohort study using the provincial health administrative and population databases from fi ve Canadian provinces: Alberta, Manitoba, Nova Scotia, Ontario, and Quebec. Th ese databases contain records of all legal residents of each province, representing a source population of 26,530,074 people, 79.2% of the Canadian population ( 14 ) .
CanGIEC conducted a distributed network analysis in which the same methodology was applied to each Canadian province's health administrative data to produce standardized estimates of incidence and prevalence in each province. In addition, we determined trends over time by age group: overall (6 months to 15.9 years (y) at diagnosis), and in sub-groups: 6 months to 4y, 5-9y, 10-13y, and 14-15.9y at diagnosis or at the time of the point prevalence estimate. Standardized estimates and trends were then combined by meta-analysis using random-eff ects models analysis to account for heterogeneity. Th is method has been used previously to conduct observational pharmaco-epidemiology research in Canada and the United Kingdom ( 15 ) .
Population
To create the cohort, we identifi ed all children <16y at the time of IBD diagnosis in each province. For incident cases, we excluded people with discontinuous health care coverage within the province, such as those who left a province and then returned. Incident cases diagnosed <6 months old were also excluded due to the risk of misclassifi cation with allergic or other non-IBD causes of enterocolitis. We used validated algorithms to identify persons with IBD for the provinces of Alberta, Manitoba, and Ontario ( 7, 16, 17 ) . Th ese algorithms (see Supplementary Table 1 ) online consisted of combinations of outpatient, hospitalization and procedural codes to accurately distinguish IBD cases from the rest of the population, and have all been validated as the most accurate identifi cation method for the province in which they were applied. Th e Ontario algorithm was validated and found to be accurate in a population of children with and without IBD from academic and community practices, treated by pediatric gastroenterologists, adult gastroenterologists, and primary care providers ( 7 ) . Th e Manitoba algorithm was also validated using a random sample chart review from across the province. Although most pediatric patients with IBD were treated in a single-academic center in Winnipeg, the algorithm identifi ed 95% of those patients ( 17 ) . Th e Alberta algorithm was validated using a reference standard derived from endoscopy reports from the Calgary Health Region and Capital Health Region and included both academic and community practices ( 16 ) . Of note, Quebec cases were identifi ed using a modifi ed version of the Alberta algorithm ( 12 ) , and Nova Scotia cases were identifi ed using the Ontario pediatric algorithm ( 7 ) . To ensure that the lack of validated algorithms in Quebec and Nova Scotia had not altered study conclusions, we conducted a sensitivity analysis without these provinces included.
Th e date of diagnosis was defi ned as the date of the fi rst health care contact (either outpatient or hospitalization) within the identifi cation algorithm with associated International Classifi cation of Disease (ICD), ninth-revision (ICD-9) or ICD, tenth revision (ICD-10) for Crohn's disease (CD) or ulcerative colitis (UC): 555.x, 556.x, K50.x, or K51.x. For the incident estimates in all provinces, we applied validated look-back and look-forward qualifi cation periods. Th e 3-year look-back period has been demonstrated to successfully diff erentiate incident from prevalent cases in 95% of Ontario children ( 7 ) . A look-back period was not applied in cases where full administrative data was available from birth. In order to qualify as an IBD case, we allowed for the combination of codes to occur within a 3-year interval, which has also been validated as adequate in Ontario children ( 7 ) . Using these look-back and qualifi cation periods, we created study cohorts of incidence and prevalence of childhood IBD from [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] In children with IBD, validated algorithms were used to classify them as CD, UC, or IBD type unclassifi able (i.e., cases for whom the algorithm could not distinguish CD or UC classification; see Supplementary Table 1 ). Disease classifi cation was provided for both the initial diagnosis (grouping of diagnostic codes associated with health care contacts immediately aft er the date of diagnosis) and latest diagnosis (most recent grouping of health care contacts available for each case). For the purposes of incidence and prevalence estimates, the latest diagnosis was used to refl ect the treating physicians' best assessment of disease classifi cation at the end of the study period. Th erefore, if a subject's diagnosis changed from UC to CD, they were counted as CD for the incidence and prevalence estimates and for the calculation of time trends.
Data sources
Health administrative data from all provinces consisted of outpatient physician billing records, and hospitalization records. Th e databases used to identify cases were described in detail in the studies describing validation of the identifi cation algorithms ( 7, 16, 17 ) . In the case of all fi ve provinces, a record of the full IBD population was available to investigators for analysis. In Ontario and Nova Scotia, the full non-IBD population of the province was available to investigators. However, in Alberta, Manitoba, and Quebec general population estimates from the 2001 and 2006 Canadian censuses were used to determine the denominator of incidence and prevalence rates, and to calculate inter-censal population estimates.
Statistical analysis
Descriptive statistics were reported as medians with interquartile range (IQR), or proportions where appropriate. Sex-and age-standardized annual prevalence and incidence per 100,000 population were determined for each province for the fi scal years (1 April to 31 March) in which data was available, with corresponding 95% confi dence intervals (CI) based on Gamma distribution ( 18 ) . Yearly and overall rates for the age groups (6 months to 4y, 5-9.9y, 10-13.9y, 14-15.9y) were standardized by sex only, with standard populations consisting of at-risk people within the appropriate age group. Trends in incidence over time were reported as an annual percentage change (APC) over the study period by exponentiating the beta coeffi cient of the sexadjusted Poisson regression and subtracting it by one (exp(β )-1). Th is Poisson model was also used to assess statistical signifi cance in trends in incidence over time, stratifi ed by age category with age-appropriate denominator populations. An APC is statistically signifi cant when its 95% CI does not cross zero. Analyses were conducted using SAS v9.4 (SAS Institute Inc., Cary, NC, USA).
Meta-analysis using random-eff ects models was used to produce national estimates of incidence and prevalence. Incidence and prevalence estimates with 95% CIs were reported for each year, and for the overall study period. We assessed trends in incidence and prevalence over time, stratifi ed by age groups, by meta-analyzing the APC for each province using random-eff ects models. Only standardized estimates were included in meta-analyses ( 19 ) . Heterogeneity was calculated using the I 2 statistic and Cochrane χ 2 test ( Q -test), which describe the percentage of total variation across incidence estimates due to heterogeneity rather than chance. We conducted a sensitivity analysis to determine APC in incidence and prevalence excluding provinces without a validated algorithm (Quebec and Nova Scotia). Meta-analyses were conducted with STATA statistical soft ware version 11 (STATA Corp, College Station, TX, USA).
RESULTS
Descriptive characteristics
A total of 5,214 incident cases and 6,554 prevalent cases were included in the study population. Th e study cohorts are described in Table 1 . For the incidence cohort, the characteristics of the populations in each province were similar. One exception was the greater predominance of CD in Quebec compared to other provinces for initial diagnosis (86.4 vs. 57.7%). Similar results were seen for latest diagnosis (88.5 vs. 59.1%) Th e median age at diagnosis (for overall cohort: 12.3y, IQR 10.5-14.1) and sex distribution (females 43.3%) was not signifi cantly diff erent between provinces. Th e sex distribution was not signifi cantly diff erent between age groups, with a male majority present in all pediatric age groups ( Supplementary Table 2 ).
Incidence
For the full study period, the overall standardized incidence for all provinces was 9.7 (95% CI 9.1-10.2) per 100,000. Th e incidence by province is demonstrated in Table 2 and Figure 1a . Th e incidence of IBD in all years was lowest for Manitoba (7.2 per 100,000) and highest in Nova Scotia (15.2 per 100,000), with signifi cant heterogeneity amongst provinces ( I 2 76.3%, P <0.001). Similar variation across provinces was present for CD (overall incidence 6.5 per 100,000) and UC (overall incidence 2.4 per 100,000). For CD, both Nova Scotia (9.3 per 100,000) and Quebec (8.8 per 100,000) had higher incidence compared to other provinces. Quebec had a lower incidence of UC compared to other provinces (1.0 per 100,000).
Th e incidence of IBD over the study period is demonstrated in Figure 2 . Overall incidence per 100,000 children changed from 7.9 (95% CI 6.4 to 9.4) in 1999 to 10.6 (95% CI 8.5 to 12.6) in 2008, the fi nal year that all provinces could contribute data. In 2010, when only Ontario and Manitoba could provide data, the combined incidence was 9.0 (95% CI 4.4 to 13.5) per 100,000. Change in
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incidence over time is demonstrated in Figure 3 , with graphical representation on a map in Figure 4a . For children <16y, the incidence increased over time in Ontario (APC +5.8%, 95% CI +4.6 to +7.0%) and Quebec (APC +2.8%; 95% CI +0.9 to +4.7%). Incidence did not change over time in Alberta (APC +1.5%, 95% CI −1.2 to +4.2%), Manitoba (APC −1.4%, 95% CI −5.2 to +2.4%), or Nova Scotia (APC −0.8%, 95% CI −5.8 to +4.2%). Overall, the combined incidence rate was stable (APC +2.1%; 95% CI −0.06 to +4.8%). Signifi cant heterogeneity was observed between provinces in APCs over time ( I 2 84.3%, P <0.001). Incidence rates were also stable over time when IBD was stratifi ed into CD (APC +1.7%; 95% CI −1.0 to +4.4%) and UC (APC +1.7%; −3.8% to +7.1%). Th e only age group with statistically signifi cant increased incidence was children 6 month to 5y (APC +7.2%; 95% CI +2.8 to 11.6%). In this youngest group, incidence did not rise signifi cantly when stratifi ed by CD (APC +3.2%; 95% CI −3.2 to +9.7%) and UC (APC +5.5%; 95% CI −0.3% to +11.4%). Of note, signifi cant heterogeneity was not present amongst provinces for this age group (IBD: I 2 9.5%, P =0.35; CD: I 2 0.0%, P =0.84; UC: I 2 0.0%, P =0.50). Due to the rarity of cases of children <5y, the rate change models did not converge for Manitoba in calculation of IBD trends, nor for Manitoba and Nova Scotia in calculation of CD and UC trends.
Results of the sensitivity analysis excluding Nova Scotia and Quebec are presented in Supplementary Figure 1 . Excluding provinces without validated identifi cation algorithms did not signifi cantly alter APC of incidence.
Prevalence
Based on meta-analysis, the standardized period prevalence for all provinces was 38.2 (95% CI 35.8 to 40.7) per 100,000 children. Th e prevalence by province is demonstrated in Table 2 and Figure 1b . In 2008, the fi nal year in which all provinces reported data, the Benchimol et al. Benchimol et al.
with IBD every year, and 2,695 children under 16y were living with IBD in Canada in 2008. Th e high incidence and prevalence of pediatric IBD in Canada has been demonstrated in previous single-province studies ( 9, 12, 20 ) . In our study, the incidence of IBD in children was amongst the highest in the world which is consistent with the only previous multi-province Canadian study ( 21 ) . A previous systematic review which included studies published before 2010 demonstrated that only Norway had similar incidence, 10.6 per 100,000 children <16y ( 22 ) . More recently, a study from Stockholm County, Sweden reported an incidence of 12.8 per 100,000 in children <16y between 2002-2007, signifi cantly increased from previous reports from the same region ( 23 ) . By contrast, incidence estimates from other regions of Europe and the United States were signifi cantly lower ( 1 ) . Th e reasons for the higher rates in children from Canada and Northern Europe are not known. Lack of sunlight exposure and high rates of vitamin D defi ciency, antibiotic use, diet, and migration patterns have been hypothesized as contributors ( 4, 24 ) . Th e interaction between environmental risk factors, the intestinal microbiome, and genetic predisposition are important areas under investigation. Th is trend of increased incidence in the northern latitude has also been demonstrated in the United States ( 25 ) . Even amongst northern states, incidence may be increasing. A recent population-based study from Rhode Island demonstrated a much higher incidence of IBD in children and adults ( 26 ) compared with older estimates from Wisconsin ( 27 ) and Minnesota ( 28 ) . It remains to be seen whether American states at northern latitudes will develop a similarly high incidence of pediatric IBD noted in Canada over the past two decades.
Th e incidence of pediatric IBD was stable during the study period, with the exception of incidence in children under 5 years old. Th e rise in the incidence of very early onset IBD (VEO-IBD) ( 29 ) national point prevalence was 46.2 (95% CI 34.6 to 57.8) per 100,000, signifi cantly increased from the prevalence in 2000 of 33.2 (95% CI 26.6 to 39.8) per 100,000. Overall, the prevalence for CD was 25.5 (95% CI 22.8 to 28.1) per 100,000. For UC, prevalence was 10.7 (95% CI 9.8 to 11.6) per 100,000. 
DISCUSSION
Using a distributed network methodology applied to fi ve Canadian population-based health administrative databases, we confi rmed that Canada has amongst the highest incidence and prevalence of childhood-onset IBD in the world. As previously reported, the predominant form of pediatric-onset IBD is CD, with more boys than girls aff ected. Th e incidence of childhoodonset IBD was stable during the fi rst decade of the twenty-fi rst century, with the exception of rising incidence among children diagnosed under the age of 5y. Finally, we noted signifi cant heterogeneity in both incidence and trends over time amongst provinces despite use of standardized analysis, indicating signifi cant regional variation. Extrapolating our results to the entire country, we estimate that approximately 600-650 children are diagnosed 
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Epidemiology of Pediatric IBD in Canada in our study population was consistent across all provinces as evidence by the lack of statistical heterogeneity between provinces. Th e rapid increase in VEO-IBD was previously noted in Ontario ( 8 ). Th is multi-province study demonstrated that incidence was rising by ~7% per year in that age group, with little heterogeneity amongst provinces. Th is fi nding may also explain the observation of increased prevalence of children <16y living with IBD, since these VEO-IBD cases would remain in the cohort for longer. INFLAMMATORY BOWEL DISEASE VOLUME 112 | JULY 2017 5-9.9 5-9.9 5-9.9 5-9.9 5-9.9 5-9.9 5-9.9 5-9.9 10-13.9 10-13.9 10-13.9 10-13.9 10-13.9
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14-15.9 14-15.9 14-15.9 14-15. 5-9.9 5-9.9 5-9.9 10-13.9 10-13.9 10-13.9 10-13.9 10-13.9 Figure 3 . Annual percentage change in incidence of ( a ) IBD, ( b ) CD, and ( c ) UC by age group. Meta-analysis was conducted to combine provincial estimates. I 2 was calculated to determine heterogeneity in provincial results.
Epidemiology of Pediatric IBD in Canada played a role in the observed increased incidence ( 4 ) . Th e association between early-life environmental factors and childhood-onset IBD was particularly noted in studies demonstrating increased risk due to early-life antibiotic ( 31 ) and air pollution exposure ( 32 ) . However, changes in health services factors may also have resulted in increased recognition in young children. Whereas all studies relying on administrative database are subject to misclassifi cation errors on the study population, this bias is less likely in children under the age of 5 years because a previous validation study showed that only 1% of children diagnosed <6y did not have any health services contacts with associated IBD diagnoses at the end of a mean 9y follow-up period ( 8 ) . Th is means that most children initially labeled IBD continued to be treated as IBD years later. Th ere was signifi cant heterogeneity in estimates of incidence, prevalence, and trends over time for those diagnosed above 5y old, indicating variation between provinces. In particular, we noted that Nova Scotia demonstrated signifi cantly higher incidence and prevalence of IBD compared with other provinces. In addition, Quebec demonstrated a much greater proportion of IBD patients being classifi ed as having CD compared with UC. Both of these fi ndings were demonstrated in other adult-focused cohort studies, and remain unexplained ( 12, 21 ) . Diff erent genetic backgrounds may play a role. Quebec is primarily comprised of a unique French Canadian (Quebecois) population with a distinct phenotype ( 33 ) . Nova Scotia is comprised of 31% of people of Scottish origin and 28% of people from other British Isles (compared to 15 and 20%, respectively, in all Canadians) ( 34 ) , and Scotland has been noted to have a higher incidence of pediatric IBD than the rest of the United Kingdom ( 35 ) . Finally, Ontario and Quebec have larger immigrant populations than other provinces, and Manitoba has a higher First Nations population than other provinces. Immigrants and First Nations people have been demonstrated to have lower rates of IBD than other Canadians (36) (37) (38) . Finally, the diff erences in incidence observed amongst provinces may be related to access to health services. If families from Nova Scotia are more likely to seek medical attention for their children, this would explain the higher incidence observed. Of note, pediatric asthma prevalence was also reported to be higher in Nova Scotia than other provinces ( 39 ) . Future research will examine the issue of access and variation of care of children with IBD in Canada.
Th e rising incidence of VEO-IBD, and particularly in children under 5 years has important clinical implications. Children with onset of disease at younger ages have been demonstrated to have lower rates of hospitalization, emergency department utilization and surgical resection ( 8, (40) (41) (42) . However, these patients will live longer with the disease and research regarding long-term outcomes is lacking. In addition, young children present more frequently with isolated colonic disease, with a change to a more ileo-colonic phenotype in children presenting between 6-9 years old ( 40, 42 ) . Th erefore, it is much more diffi cult to determine IBD sub-type in children under 6 years presenting with colitis, which may impact medication choice, and the decision on whether to proceed to colectomy in patients failing medical management. Finally, the psycho-social impact on the family of caring for a young child with a chronic illness is signifi cant. Th is may be refl ected in the need for age-appropriate educational material, decisions regarding medical or dietary therapy, when to proceed to surgery, frequent school absences for the child, or parental absences from work. Th ese issues may be best addressed in centers off ering multi-disciplinary care such as support from a psychologist, social worker, dietitian, and specialized nurse. In light of these unique challenges in very young children with IBD, we recommend that these patients be treated by specialized pediatricians with expertise in multi-disciplinary IBD care. In addition, we would suggest that the Paris classifi cation would acknowledge the rising incidence and the uniqueness of this cohort, and encourage further research into etiology, natural history and therapeutic options in young children.
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Limitations
Misclassifi cation bias can always aff ect research using routinely collected health data ( 43 ) , and the heterogeneity observed amongst provincial results may have been due to the use of different algorithms to identify IBD patients in each province. We used the most accurate identifi cation and classifi cation algorithms for each specifi c province to reduce the risk of misclassifi cation error, and the algorithms used were validated in the provinces to which they were applied (for Alberta, Manitoba, and Ontario). In contrast, Nova Scotia and Quebec applied non-validated coding algorithms and were the provinces with the most inconsistent fi ndings. A sensitivity analysis that included only provinces that identifi ed patients with locally validated algorithms did not demonstrate diff erent fi ndings. Nonetheless, no administrative data algorithm is completely accurate, and diff erential accuracies may have resulted in the appearance of heterogeneity. Future work will continue to develop and validate algorithms to identify patients with IBD, and to identify the causes of the variation seen across Canadian provinces.
Th is study was also limited by the time periods of data availability, and particularly by the requirement for look-back and lookforward periods to diff erentiate incident from prevalent cases. While use of these validated periods ensured accurate estimates of incidence, we were unable to determine trends in incidence prior to or aft er the study period. In addition, our analysis was able to determine overall ecological trends in IBD epidemiology, but not the reasons for the observed changes. Future research should determine whether changing environmental risk factors, new gene-environment interactions and/or alterations to the health system resulted in the changing rates.
CONCLUSIONS
In summary, we have demonstrated that Canada has amongst the highest rates of childhood-onset IBD in the world. While the incidence of IBD has stabilized in children over the age of 5 years, the incidence is rising rapidly in children under 5 years old. Th ese fi ndings have important implications on the children, their families, and the health care system, because these children will live longer with the disease, have a more extensive disease phenotype, and result in higher direct costs for IBD care compared with adults ( 6, 44 ) . In addition, the increasingly early age of onset implies early-life environmental triggers in at-risk patients. Since young children are exposed to fewer environmental triggers in the course of their short lives, future research should focus on identifi cation of triggers in children with IBD, understanding the biology behind changes resulting in disease, and intervention to prevent the occurrence of IBD in this vulnerable age group.
